HER2-positive metastatic breast cancer: New agents on the horizon
Publication in refereed journal


香港中文大学研究人员 ( 现职)

杨明明教授 (肿瘤学系)

全文

没有全文档案提供

引用次数
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/1Scopus source URL

其它资讯

摘要The human epidermal growth factor receptor HER2/neu gene is amplified and overexpressed in 25 to 30% of breast cancers. In women with HER2-positive advanced or metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab and the dual tyrosine kinase inhibitor lapatinib are both established options used in combination with cytotoxic chemotherapy. In patients who progress after first-line therapy with trastuzumab plus chemotherapy, continued trastuzumab or switching to lapatinib, both in combination with cytotoxic chemotherapy, offers clinical benefit. New agents in the metastatic disease setting include pertuzumab and trastuzumab emtansine. In the first-line setting, the addition of pertuzumab to trastuzumab/docetaxel yields longer median progression-free survival than placebo plus trastuzumab/docetaxel (http://aims.cuhk.edu.hk/converis/portal/Publication/18.5 vs. http://aims.cuhk.edu.hk/converis/portal/Publication/12.4 months; p < 0.00http://aims.cuhk.edu.hk/converis/portal/Publication/1). In the second-line setting, trastuzumab emtansine alone improves median progression-free survival compared with capecitabine plus lapatinib (9.6 vs. 6.4 months; p < 0.000http://aims.cuhk.edu.hk/converis/portal/Publication/1). The combination of trastuzumab emtansine plus pertuzumab has also shown encouraging preliminary activity. Other agents in clinical development include subcutaneous trastuzumab, afatinib, and neratinib. Numerous other treatments across a range of drug classes are currently in development for the treatment of HER2-positive metastatic breast cancer. ? 20http://aims.cuhk.edu.hk/converis/portal/Publication/12 Hong Kong College of Radiologists.

着者Yeo W.
期刊名称Hong Kong Journal of Radiology
出版年份20http://aims.cuhk.edu.hk/converis/portal/Publication/12
月份http://aims.cuhk.edu.hk/converis/portal/Publication/12
日期http://aims.cuhk.edu.hk/converis/portal/Publication/1
卷号http://aims.cuhk.edu.hk/converis/portal/Publication/15
期次4 SUPPL.
出版社Hong Kong Academy of Medicine Press
出版地China
页次5http://aims.cuhk.edu.hk/converis/portal/Publication/1 - 56
国际标準期刊号2223-66http://aims.cuhk.edu.hk/converis/portal/Publication/19
电子国际标準期刊号2307-4620
语言英式英语

关键词Antineoplastic agents, Breast neoplasms, Hormone replacement therapy